<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31597135</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1423-0194</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>110</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2020</Year>
            </PubDate>
          </JournalIssue>
          <Title>Neuroendocrinology</Title>
          <ISOAbbreviation>Neuroendocrinology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications.</ArticleTitle>
        <Pagination>
          <StartPage>477</StartPage>
          <EndPage>488</EndPage>
          <MedlinePgn>477-488</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1159/000504000</ELocationID>
        <Abstract>
          <AbstractText>Cabergoline is a dopamine agonist that has been used as the first-line treatment option for prolactin-secreting pituitary adenomas for several decades. It not only suppresses hormone production from these prolactinomas, but also causes tumour shrinkage. Recent studies revealed some novel mechanisms by which cabergoline suppresses tumour cell proliferation and induces cell death. In this article, we review the most recent findings in cabergoline studies, focusing on its anti-tumour function. These studies suggest the potential broader clinical use of cabergoline in the treatment of other tumours such as breast cancer, pancreatic neuroendocrine tumours, and lung cancer.</AbstractText>
          <CopyrightInformation>Â© 2019 S. Karger AG, Basel.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lin</LastName>
            <ForeName>Shaojian</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Pituitary Tumour, Department of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Anke</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Xun</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Neuroendocrine Research Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Zhe Bao</ForeName>
            <Initials>ZB</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Pituitary Tumour, Department of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, zhebaowu@aliyun.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Neuroendocrinology</MedlineTA>
        <NlmUniqueID>0035665</NlmUniqueID>
        <ISSNLinking>0028-3835</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LL60K9J05T</RegistryNumber>
          <NameOfSubstance UI="D000077465">Cabergoline</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077465" MajorTopicYN="N">Cabergoline</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047748" MajorTopicYN="N">Pituitary ACTH Hypersecretion</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010911" MajorTopicYN="N">Pituitary Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015175" MajorTopicYN="N">Prolactinoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Cabergoline</Keyword>
        <Keyword MajorTopicYN="Y">Pituitary adenomas</Keyword>
        <Keyword MajorTopicYN="Y">Prolactinoma</Keyword>
        <Keyword MajorTopicYN="Y">Resistance mechanism</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31597135</ArticleId>
        <ArticleId IdType="doi">10.1159/000504000</ArticleId>
        <ArticleId IdType="pii">000504000</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
